{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:28:38Z","timestamp":1768217318844,"version":"3.49.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>People with HIV and chronic hepatitis C may develop metabolic complications after sustained virologic response (SVR), possibly due to persistent molecular alterations induced by HCV. This study aimed to identify baseline (pre-treatment) lipid and immune biomarkers associated with post-SVR metabolic events in HIV\/HCV-coinfected participants with compensated advanced chronic liver disease (cACLD) receiving long-term suppressive antiretroviral therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of 56 HIV\/HCV-coinfected participants with cACLD. Untargeted lipidomic profiling was performed on baseline plasma samples using a liquid-chromatography-mass spectrometer. The outcome was the development of metabolic events (diabetes mellitus and\/or hyperlipidemia) during follow-up, up to seven years post-HCV treatment. Statistical analyses included orthogonal partial least squares discriminant analysis (OPLS-DA), Cox regressions models, and Spearman correlations with inflammation-related biomarkers and immune checkpoint proteins, with multiple comparison corrections using the false discovery rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>25% participants developed metabolic events after SVR. OPLS-DA identified 163 lipid species (VIP scores\u22651) associated with these events, and adjusted Cox regression confirmed significant associations for 24 of them. Lysophosphatidylcholines (LPCs) were the most prevalent, with higher baseline levels linked to increased metabolic risk. Participants who developed events also had higher levels of plasmalogens LPC (O-LPC), lysophosphatidylethanolamine (LPE), lysophosphatidylinositol (LPI), lysophosphatidic acid (LPA), and phosphosphatidylcholine (PC). Several lipid species correlated positively with the pro-inflammatory cytokine IL-18, the anti-inflammatory suppressor IL-1RA, and the immune checkpoint proteins IDO and S100A8\/A9.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Pre-treatment lipid and immune dysregulation was associated with post-SVR metabolic events in HIV\/HCV-coinfected participants, suggesting that HCV may leave a lasting metabolic imprint that contributes to adverse outcomes after viral clearance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1674837","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:14:58Z","timestamp":1768205698000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid and immune dysregulation and risk of metabolic disorders after HCV clearance in HIV\/HCV-coinfected participants with cACLD: a retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ana","family":"Virseda-Berdices","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belen","family":"Requena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Gonzalez-Riano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Honta\u00f1on","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coral","family":"Barbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Resino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Mart\u00edn-Escolano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Jim\u00e9nez-Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/biomedicines11020271","article-title":"Hepatitis C virus-lipid interplay: pathogenesis and clinical impact","volume":"11","author":"Elgretli","year":"2023","journal-title":"Biomedicines"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.62347\/EQIR8735","article-title":"Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus","volume":"14","author":"Hsu","year":"2024","journal-title":"Am J Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16346","article-title":"MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective","volume":"53","author":"Fouad","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15976","article-title":"Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination","volume":"52","author":"Ogawa","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13167","article-title":"Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response","volume":"26","author":"Peleg","year":"2019","journal-title":"J Viral Hepat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06457-2","article-title":"Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C","volume":"66","author":"Benhammou","year":"2021","journal-title":"Dig Dis Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15575","article-title":"Systematic review: chronic viral hepatitis and metabolic derangement","volume":"51","author":"Wang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.17","article-title":"HCV and HIV co-infection: mechanisms and management","volume":"11","author":"Chen","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25791","article-title":"Hepatic steatosis and steatohepatitis in human immunodeficiency virus\/hepatitis C virus-coinfected patients","volume":"56","author":"Macias","year":"2012","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40506-019-00207-3","article-title":"Metabolic syndrome in HIV\/HCV co-infected patients","volume":"11","author":"Collins","year":"2019","journal-title":"Curr Treat Options Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80065-3","article-title":"Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease","volume":"32","author":"Zein","year":"2000","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3157","article-title":"Prevalence of diabetes in liver cirrhosis: A systematic review and meta-analysis","volume":"35","author":"Lee","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31638-2","article-title":"Prevalence of type 2 diabetes mellitus and chronic liver disease: a retrospective study of the association of two increasingly common diseases in Mexico","volume":"9","author":"Kobashi-Margain","year":"2010","journal-title":"Ann Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03093.x","article-title":"High prevalence of diabetes mellitus in patients with liver cirrhosis","volume":"27","author":"Wlazlo","year":"2010","journal-title":"Diabetes Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00508-019-01544-5","article-title":"Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease","volume":"131","author":"Unger","year":"2019","journal-title":"Wien Klin Wochenschr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","article-title":"Fibrosis regression after eradication of hepatitis C virus: from bench to bedside","volume":"160","author":"Rockey","year":"2021","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2019.1599284","article-title":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in HIV infection: a metabolic approach of an infectious disease","volume":"13","author":"Coronel-Castillo","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa502","article-title":"Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis","volume":"71","author":"Diez","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.11.004","article-title":"Burden of significant liver damage in people living with HIV after microelimination of the hepatitis C virus","volume":"86","author":"Santos","year":"2023","journal-title":"J Infect"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i13.1267","article-title":"Metabolic complications of hepatitis C virus infection","volume":"27","author":"Chaudhari","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008181","article-title":"Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals","volume":"15","author":"Perez","year":"2019","journal-title":"PloS Genet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2337\/diacare.26.2007.s5","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","year":"2003","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s42003-023-05680-7","article-title":"LiLA: lipid lung-based ATLAS built through a comprehensive workflow designed for an accurate lipid annotation","volume":"7","author":"Fern\u00e1ndez Requena","year":"2024","journal-title":"Commun Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1021\/acs.jproteome.8b00720","article-title":"CEU mass mediator 3.0: A metabolite annotation tool","volume":"18","author":"Gil-De-La-Fuente","year":"2019","journal-title":"J Proteome Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1039\/c5an01638j","article-title":"Intra-batch effect correction in liquid chromatography-mass spectrometry using quality control samples and support vector regression (QC-SVRC)","volume":"140","author":"Kuligowski","year":"2015","journal-title":"Analyst"},{"key":"B29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/metabo11080488","article-title":"Investigating global lipidome alterations with the lipid network explorer","volume":"11","author":"Kohler","year":"2021","journal-title":"Metabolites"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037487","article-title":"Elevated plasma ceramides are associated with antiretroviral therapy use and progression of carotid artery atherosclerosis in HIV infection","volume":"139","author":"Zhao","year":"2019","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.4025","article-title":"Association of lipidomic profiles with progression of carotid artery atherosclerosis in HIV infection","volume":"4","author":"Chai","year":"2019","journal-title":"JAMA Cardiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0100","article-title":"High-coverage targeted lipidomics reveals novel serum lipid predictors and lipid pathway dysregulation antecedent to type 2 diabetes onset in normoglycemic chinese adults","volume":"42","author":"Lu","year":"2019","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jcjd.2019.07.003","article-title":"Dyslipidemia management in adults with diabetes","volume":"44","author":"Lazarte","year":"2020","journal-title":"Can J Diabetes"},{"key":"B34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1210\/clinem\/dgab011","article-title":"Plasma lipidomic profiles and risk of diabetes: 2 prospective cohorts of HIV-infected and HIV-uninfected individuals","volume":"106","author":"Zhang","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05611-3","article-title":"Associations of plasma glycerophospholipid profile with modifiable lifestyles and incident diabetes in middle-aged and older Chinese","volume":"65","author":"Chen","year":"2022","journal-title":"Diabetologia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0840","article-title":"Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial","volume":"41","author":"Razquin","year":"2018","journal-title":"Diabetes Care"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0495","article-title":"Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach","volume":"62","author":"Floegel","year":"2013","journal-title":"Diabetes"},{"key":"B38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cbi.2015.01.023","article-title":"Plasma lipidomics reveal profound perturbation of glycerophospholipids, fatty acids, and sphingolipids in diet-induced hyperlipidemia","volume":"228","author":"Miao","year":"2015","journal-title":"Chem Biol Interact"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2018.07.004","article-title":"Identification of lysophosphatidylcholines and sphingolipids as potential biomarkers for acute aortic dissection via serum metabolomics","volume":"57","author":"Zhou","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-012-0434-x","article-title":"Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholine","volume":"61","author":"Hung","year":"2012","journal-title":"Inflammation Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/ijms20051149","article-title":"An updated review of lysophosphatidylcholine metabolism in human diseases","volume":"20","author":"Law","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.02.012","article-title":"Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment","volume":"196","author":"Iwase","year":"2008","journal-title":"Atherosclerosis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1134\/S1607672910040010","article-title":"Disorders of tissue transformations of lysophosphatidylcholines at experimental pancreatic diabetes in white rats and peculiarities of the corrective effect of low-energy laser radiation of an extremely low intensity","volume":"433","author":"Burlakova","year":"2010","journal-title":"Dokl Biochem Biophys"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1139\/y11-021","article-title":"Protective effect of neferine on endothelial cell nitric oxide production induced by lysophosphatidylcholine: the role of the DDAH-ADMA pathway","volume":"89","author":"Peng","year":"2011","journal-title":"Can J Physiol Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"117443","DOI":"10.1016\/j.lfs.2020.117443","article-title":"The mechanisms of lysophosphatidylcholine in the development of diseases","volume":"247","author":"Liu","year":"2020","journal-title":"Life Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cellimm.2010.08.003","article-title":"Importance of lipid rafts for lysophosphatidylcholine-induced caspase-1 activation and reactive oxygen species generation","volume":"265","author":"Schilling","year":"2010","journal-title":"Cell Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00420-09","article-title":"Single lysophosphatidylcholine components exhibit adjuvant activities in vitro and in vivo","volume":"17","author":"Bach","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2174\/092986709788682164","article-title":"Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis","volume":"16","author":"Lessig","year":"2009","journal-title":"Curr Med Chem"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i3.456","article-title":"Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus","volume":"6","author":"Tangvarasittichai","year":"2015","journal-title":"World J Diabetes"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.781417","article-title":"Lipidomics reveals serum specific lipid alterations in diabetic nephropathy","volume":"12","author":"Xu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4069-2","article-title":"Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS","volume":"59","author":"Lu","year":"2016","journal-title":"Diabetologia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2014.11.020","article-title":"Lysophospholipid receptors in drug discovery","volume":"333","author":"Kihara","year":"2015","journal-title":"Exp Cell Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/metabo6010006","article-title":"Lysophosphatidylinositol signalling and metabolic diseases","volume":"6","author":"Arifin","year":"2016","journal-title":"Metabolites"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0649","article-title":"The L-alpha-lysophosphatidylinositol\/GPR55 system and its potential role in human obesity","volume":"61","author":"Moreno-Navarrete","year":"2012","journal-title":"Diabetes"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1199","article-title":"Plasma lipidome and prediction of type 2 diabetes in the population-based malmo diet and cancer cohort","volume":"43","author":"Fernandez","year":"2020","journal-title":"Diabetes Care"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074341","article-title":"Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes","volume":"8","author":"Meikle","year":"2013","journal-title":"PloS One"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041456","article-title":"Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes","volume":"7","author":"Barber","year":"2012","journal-title":"PloS One"},{"key":"B58","doi-asserted-by":"publisher","first-page":"0629","DOI":"10.34133\/research.0629","article-title":"Targeting lysophosphatidic acid ameliorates dyslipidemia in familial hypercholesterolemia","volume":"8","author":"Du","year":"2025","journal-title":"Res (Wash D C)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2891-3","article-title":"Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice","volume":"56","author":"Rancoule","year":"2013","journal-title":"Diabetologia"},{"key":"B60","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1210\/er.2007-0025","article-title":"Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism","volume":"29","author":"Holland","year":"2008","journal-title":"Endocr Rev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3390\/biom10101457","article-title":"Updating phospholipase A(2) biology","volume":"10","author":"Murakami","year":"2020","journal-title":"Biomolecules"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3389\/fimmu.2019.0292","article-title":"Lysophosphatidylcholine induces NLRP3 inflammasome-mediated foam cell formation and pyroptosis in human monocytes and endothelial cells","volume":"10","author":"Correa","year":"2019","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.04.025","article-title":"A 360 degrees view of the inflammasome: Mechanisms of activation, cell death, and diseases","volume":"186","author":"Barnett","year":"2023","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment","volume":"13","author":"Ihim","year":"2022","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/ijms20030649","article-title":"Interleukin-18 in health and disease","volume":"20","author":"Yasuda","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1475-2840-9-11","article-title":"The role of interleukin-18 in the metabolic syndrome","volume":"9","author":"Troseid","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1957","article-title":"Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities study","volume":"35","author":"Negi","year":"2012","journal-title":"Diabetes Care"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v8.i6.304","article-title":"Interleukin-18 polymorphism as an inflammatory index in metabolic syndrome: A preliminary study","volume":"8","author":"Fatima","year":"2017","journal-title":"World J Diabetes"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27427","article-title":"Interleukin-18 and diabetic nephropathy: A review","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J Cell Physiol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25083","article-title":"The role of IDO, IL-10, and TGF-beta in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma","volume":"91","author":"Yang","year":"2019","journal-title":"J Med Virol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02248-06","article-title":"Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection","volume":"81","author":"Larrea","year":"2007","journal-title":"J Virol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nrd.2018.124","article-title":"Metabolic disorders: IDO inhibitors could change tack to treat metabolic disorders","volume":"17","author":"Cully","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0492-x","article-title":"Elevated serum levels of S100A8\/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients","volume":"17","author":"Chen","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1038\/ncomms7915","article-title":"Extracellular MRP8\/14 is a regulator of beta2 integrin-dependent neutrophil slow rolling and adhesion","volume":"6","author":"Pruenster","year":"2015","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2021.10.004","article-title":"S100A8\/A9 in COVID-19 pathogenesis: Impact on clinical outcomes","volume":"63","author":"Mellett","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.07.015","article-title":"S100A8\/A9: From basic science to clinical application","volume":"167","author":"Pruenster","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007419","article-title":"Calprotectin\u2013a novel marker of obesity","volume":"4","author":"Mortensen","year":"2009","journal-title":"PloS One"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0374","article-title":"Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes","volume":"167","author":"Ortega","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00144","article-title":"Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss","volume":"17","author":"Catalan","year":"2011","journal-title":"Mol Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1159\/000478097","article-title":"S100A8\/A9 (Calprotectin), Interleukin-6, and C-Reactive Protein in Obesity and Diabetes before and after Roux-en-Y Gastric Bypass Surgery","volume":"10","author":"Lylloff","year":"2017","journal-title":"Obes Facts"},{"key":"B82","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/1471-2105-14-338","article-title":"MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach","volume":"14","author":"Nyamundanda","year":"2013","journal-title":"BMC Bioinf"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1674837\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:15:00Z","timestamp":1768205700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1674837\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2025.1674837"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1674837","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1674837"}}